CAPS, NOMID and DIRA: Rare Autoinflammatory Diseases in Children

A Baby With Fevers, Rash and Swollen Joints That Never Fully Go Away

Written By: Nitin Goswami, Senior Medical Content Writer  |  Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)

Most parents whose child has one of these diseases spend years being told it's "just" recurring infections, allergies or growing pains. That's not a criticism of anyone; these conditions are so rare that many pediatricians will never see a case in their career. This guide walks through what CAPS and DIRA actually are, why they happen, and why one particular medicine changed the outlook for children born with them.

CAPS, NOMID and DIRA at a Glance

What Are Cryopyrin-Associated Periodic Syndromes?

CAPS isn't one disease but a spectrum of three, all caused by mutations in a single gene, NLRP3, which builds a protein that normally sits quietly inside immune cells. When the gene is faulty, that protein gets stuck in the "on" position, constantly telling the body to release interleukin-1, a chemical messenger that triggers fever, rash and inflammation.

The Three Faces of CAPS

• Familial Cold Autoinflammatory Syndrome (FCAS): the mildest form, with flares often triggered by cold exposure
• Muckle-Wells Syndrome (MWS): moderate disease, with a risk of progressive hearing loss and, over years, kidney damage from a complication called amyloidosis
• Neonatal-Onset Multisystem Inflammatory Disease (NOMID): the most severe form, present from birth, with continuous inflammation that can affect the brain, eyes, ears and bones

Why Diagnosis Often Takes So Long

An Australian nationwide survey that identified 18 living CAPS patients found a striking pattern: children with NOMID were diagnosed in a median of 2.1 years, but people with the milder MWS or FCAS forms waited a median of 20.6 years for a correct diagnosis. The more severe form is easier to recognize precisely because it's so relentless; the milder forms are the ones most often mistaken for allergies or unexplained fevers for decades.

What Does NOMID Look Like in a Child?

In the Australian survey, the presenting features were consistent: urticaria-like rash was present in all NOMID and CAPS patients studied, periodic fever in 78%, joint pain in 72%, and sensorineural hearing loss in 61%. Beyond the skin and joints, NOMID can involve chronic inflammation of the lining around the brain and spinal cord, vision problems, and a distinctive overgrowth of the bone at the ends of long bones and knees.

Why It's Considered a Medical Emergency in Infancy

Left untreated, the constant inflammation in NOMID causes cumulative, often irreversible damage: hearing loss, vision loss, joint deformity and, over time, a life-threatening buildup of amyloid protein in the kidneys. That's why getting a correct diagnosis and starting treatment early matters so much for this particular form.

What Is DIRA, and How Is It Different From CAPS?

DIRA looks similar to NOMID at first glance, an infant with pustular skin lesions and bone inflammation from the first weeks of life, but it comes from a different gene entirely. DIRA is caused by mutations in IL1RN, the gene that makes the body's own natural interleukin-1 blocker. Without that built-in brake, interleukin-1 signaling runs unopposed, and the result is severe inflammation of the skin and bones, sometimes with dangerously high inflammatory markers and blood clotting complications.

DIRA was first formally described in 2009, when researchers studied nine children from six families with neonatal-onset skin pustules and bone inflammation and traced the cause to IL1RN mutations. Every child in that original group who was treated with anakinra responded rapidly.

How Are These Diseases Diagnosed?

Because the symptoms overlap with common childhood illnesses, infections and eczema, diagnosis usually needs a specialist, typically a pediatric rheumatologist or immunologist, who recognizes the pattern and orders genetic testing.

What Doctors Look For

• Onset in the newborn period or early infancy, especially with skin pustules or hive-like rash plus fever
• Blood tests showing persistently high inflammatory markers even between apparent "flares"
• Genetic testing for NLRP3 (CAPS/NOMID) or IL1RN (DIRA) mutations to confirm the diagnosis

Questions Worth Asking a Specialist

• Could this be an autoinflammatory syndrome rather than recurring infections or allergies?
• Should we test for NLRP3 or IL1RN mutations?
• Has hearing, vision and kidney function been checked as a baseline?

How Is Kineret (Anakinra) Used to Treat These Diseases?

Kineret is a lab-made copy of the body's own interleukin-1 blocker, given as a daily injection under the skin. In NOMID and DIRA, it doesn't just ease symptoms; it addresses the actual cause of the inflammation by replacing the missing brake on interleukin-1.

What the Long-Term Data Shows in NOMID

A cohort study followed 26 NOMID patients treated with anakinra for at least three years. At both 36 and 60 months, disease activity scores, pain scores and inflammatory markers were significantly improved compared with before treatment. Inflammation of the fluid around the brain and spinal cord was suppressed, and most patients had stable or improved hearing and stable vision. One honest limitation: bone lesions continued to progress in some patients despite otherwise good control, so anakinra manages the inflammation well but doesn't reverse every part of the disease.

Dosing, in Plain Terms

For NOMID and DIRA, the FDA label starts children at 1 to 2 mg per kg of body weight daily, adjustable up to a maximum of 8 mg per kg daily to control active inflammation. That's very different from the fixed 100 mg daily dose used in adult rheumatoid arthritis, because CAPS and DIRA often need higher, weight-based doses to fully control inflammation.

What to Watch For

• Injection site reactions: the most common side effect, usually mild and most likely in the first few months of treatment
• Infection risk: anakinra should not be started during an active infection, and it should be stopped if a serious infection develops
• Stopping treatment: the label notes that discontinuing anakinra in NOMID or DIRA carries a real risk of the disease flaring back, so any changes should be made with the treating specialist

Is Kineret Only for These Rare Diseases?

No. The same medicine, detailed on its Kineret product page, also has a long-standing approval for adults with moderate to severe rheumatoid arthritis who haven't responded well enough to at least one other disease-modifying drug, dosed as a fixed 100 mg daily injection. That's a different patient group and a different dosing approach from CAPS and DIRA, so this guide has focused on the rare, early-onset diseases where anakinra plays a uniquely important role.

Questions Worth Taking to Your Specialist

• Which specific diagnosis does my child have: FCAS, Muckle-Wells, NOMID or DIRA?
• What baseline tests (hearing, vision, kidney function) should we have before starting treatment?
• What dose of anakinra is right for my child's weight, and how will it be adjusted?
• What signs would mean the current dose isn't controlling inflammation well enough?
• What happens if a dose is missed or treatment needs to pause for surgery or infection?

Getting Kineret in India Through Named Patient Program

Kineret for these rare autoinflammatory diseases isn't part of the routine pharmacy supply in India. When a specialist has confirmed the diagnosis and written a prescription, Named Patient Program can help import it in the patient's own name through a regulated route. We don't diagnose or prescribe; that stays entirely with your child's specialist.

Once you have the prescription and reports ready, reach out to our access team with the documentation, and they'll walk you through timelines and next steps.

Frequently Asked Questions

What is CAPS disease in simple terms?

It's a group of three rare genetic diseases, from mild to severe, caused by a faulty NLRP3 gene that leaves the body's inflammation switch stuck on. The mildest form is FCAS, the middle form is Muckle-Wells syndrome, and the most severe is NOMID.

Is NOMID the same as CAPS?

NOMID is the most severe of the three conditions that make up the CAPS spectrum. Someone can have CAPS without having NOMID specifically, but everyone with NOMID does have a form of CAPS.

What causes DIRA, and is it the same as NOMID?

DIRA is caused by mutations in a different gene, IL1RN, which normally makes the body's natural interleukin-1 blocker. It's a separate diagnosis from CAPS and NOMID, though it can look similar at birth and is treated with the same medicine.

Can anakinra cure these diseases?

It doesn't correct the underlying gene, but by blocking interleukin-1 directly it can control inflammation very effectively for many patients, often for years, as shown in long-term follow-up studies. Some damage that occurred before treatment started, such as bone changes, may not fully reverse.

How do I get Kineret in India for my child?

Through a regulated Named Patient Program, using your specialist's prescription, your child's diagnostic and genetic test reports, and the standard government identification required for import.

Is it safe to source Kineret from an unverified online seller?

We'd strongly advise against it, especially for a child. Medicines from unverified sellers can be counterfeit, degraded or improperly stored, which is a serious risk for a daily injectable biologic. Named Patient Program sources Kineret from authorized channels with pharmacist checks, temperature-controlled shipping and batch traceability.

This article is written to help families ask better questions, not to replace a specialist's advice. CAPS, NOMID and DIRA are rare and complex, and only your child's treating specialist can advise on diagnosis and treatment based on the full clinical picture.

References

1. Australian Paediatric Surveillance Unit study. Cryopyrin-associated periodic syndrome in Australian children and adults: Epidemiological, clinical and treatment characteristics, Journal of Paediatrics and Child Health 2016.
2. Aksentijevich I, et al. An Autoinflammatory Disease With Deficiency of the Interleukin-1-Receptor Antagonist, New England Journal of Medicine 2009.
3. Sibley CH, et al. Sustained Response and Prevention of Damage Progression in Patients With Neonatal-Onset Multisystem Inflammatory Disease Treated With Anakinra: A Cohort Study to Determine Three- and Five-Year Outcomes, Arthritis and Rheumatism 2012.
4. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases, Annals of the Rheumatic Diseases 2022.
5. DailyMed (National Library of Medicine). KINERET (anakinra) Prescribing Information.
6. Swedish Orphan Biovitrum (Sobi). FDA Approves KINERET (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA), December 22, 2020.